SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Company Information
About this company
Key people
Carl Borrebaeck
Chairman of the Board
Peter Nahlstedt
Chief Executive Officer
Henrik Johansson
Chief Scientific Officer
Marianne Olsson
Vice President - Finance
Maria Agemark
Vice President - Operations
Tina Dackemark Lawesson
Vice President Marketing and Communications
Anna Cherouvrier Hansson
Vice President - Business Development
Mikael Wahlgren
Chief Legal Officer
Anki Malmborg Hager
Director
Ian Kimber
Independent Director
Paul Antony Yianni
Independent Director
Paula Zeilon
Independent Director
Click to see more
Key facts
- Shares in issue29.50m
- EPICSENZA
- ISINSE0010219626
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 159.91m
- Employees37
- ExchangeStockholm Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.